Edaravone

依达拉奉

Report date: 2026/05/25 20:02:40
NMEFirst In Class

Base Information

Drug NameEdaravone
Drug Alias NameEdaravona依迭拉奉NorphenazoneEdaravonum1-phenyl-3-methyl-5-pyrazolone +[18] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFree radicals scavengersantioxidant
TargetsFree radicals
Therapy Area/IndicationsIschemic StrokeRenal InsufficiencyAmyotrophic Lateral Sclerosis +[6] 
Global Approved IndicationsAmyotrophic Lateral SclerosisCerebral Infarction
Approved Indications in ChinaCerebral Infarction
Original Approved Country/TerritoryJapan
Original Approved Date2001/04/04
Country/TerritoryCzechiaCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMitsubishi Tanabe Pharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesMitsubishi Tanabe Pharma America IncShionogi & Co LtdMitsubishi Tanabe Pharma +[4] 
Inactive CompaniesMitsubishi Tanabe Pharma CorpNanjing Yoko Biomedical Co Ltd
Active IndicationsAmyotrophic Lateral SclerosisCerebral Infarction
Inactive IndicationsIschemic StrokeRenal InsufficiencyHepatic Insufficiency +[4] 

Other Information

ATC CodeN07XX14
Related LinksWikipediaDrugBankKEGG